These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33745570)

  • 1. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin.
    Di Pierro F; Pane M
    Clin Nutr ESPEN; 2021 Apr; 42():15-21. PubMed ID: 33745570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin.
    Di Pierro F; Bertuccioli A; Pane M; Ivaldi L
    Minerva Gastroenterol Dietol; 2019 Dec; 65(4):259-264. PubMed ID: 31646852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin: A New Horizon for Combined Approach?
    Graziano T; Amoruso A; Nicola S; Deidda F; Allesina S; Pane M; Piffanelli P; Strozzi F; Mogna L; Del Piano M
    J Clin Gastroenterol; 2016; 50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015():S153-S156. PubMed ID: 27741162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gut microflora and probiotic effects in the irritable bowel syndrome.
    Fanigliulo L; Comparato G; Aragona G; Cavallaro L; Iori V; Maino M; Cavestro GM; Soliani P; Sianesi M; Franzè A; Di Mario F
    Acta Biomed; 2006 Aug; 77(2):85-9. PubMed ID: 17172187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study].
    Yakovenko EP; Strokova TV; Ivanov AN; Iakovenko AV; Gioeva IZ; Aldiyarova MA
    Ter Arkh; 2022 Feb; 94(2):180-187. PubMed ID: 36286741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of
    Lewis ED; Antony JM; Crowley DC; Piano A; Bhardwaj R; Tompkins TA; Evans M
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
    Yuan F; Ni H; Asche CV; Kim M; Walayat S; Ren J
    Curr Med Res Opin; 2017 Jul; 33(7):1191-1197. PubMed ID: 28166427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
    Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
    Pinto-Sanchez MI; Hall GB; Ghajar K; Nardelli A; Bolino C; Lau JT; Martin FP; Cominetti O; Welsh C; Rieder A; Traynor J; Gregory C; De Palma G; Pigrau M; Ford AC; Macri J; Berger B; Bergonzelli G; Surette MG; Collins SM; Moayyedi P; Bercik P
    Gastroenterology; 2017 Aug; 153(2):448-459.e8. PubMed ID: 28483500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term probiotic administration for irritable bowel syndrome: a legal need].
    Solovyeva OI; Nekrasova AS; Topalova IG; Ponomarenko VA; Tsurtsumiia DB; Ilyashevich IG
    Ter Arkh; 2023 Oct; 95(8):679-685. PubMed ID: 38158905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of
    Sabaté JM; Iglicki F
    World J Gastroenterol; 2022 Feb; 28(7):732-744. PubMed ID: 35317278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenium-enriched
    Jin X; Hu Y; Lin T; Gao F; Xu Z; Hou X; Yin Y; Kan S; Zhu H; Chen D
    Food Funct; 2023 Jun; 14(11):5355-5374. PubMed ID: 37212199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum.
    Inturri R; Molinaro A; Di Lorenzo F; Blandino G; Tomasello B; Hidalgo-Cantabrana C; De Castro C; Ruas-Madiedo P
    Carbohydr Polym; 2017 Oct; 174():1172-1180. PubMed ID: 28821042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.